Redox Based Prodrugs for Solid Tumor Targetting

Chikhale, Prashant J.

Abstract

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Cancer Institute (NCI)
• Type: Academic Research Enhancement Awards (AREA) (R15)
• Project #: 1R15CA074377-01A2
• Application #: 2725091
• Study Section: Experimental Therapeutics Subcommittee 1 (ET)
• Program Officer: Forry-Schaudies, Suzanne L
• Project Start: 1999-05-01
• Project End: 2002-04-30
• Budget Start: 1999-05-01
• Budget End: 2002-04-30
• Support Year: 1
• Fiscal Year: 1999

Institution

• Name: University of Maryland Baltimore
• Department: Other Health Professions
• Type: Schools of Pharmacy
• DUNS #: 003255213
• City: Baltimore
• State: MD
• Country: United States
• Zip Code: 21201

Publications

Killian, Dennis M; Hermeling, Suzanne; Chikhale, Prashant J (2007) Targeting the cerebrovascular large neutral amino acid transporter (LAT1) isoform using a novel disulfide-based brain drug delivery system. Drug Deliv 14:25-31

Rautioa, Jarkko; Chikhale, Prashant J (2004) Drug delivery systems for brain tumor therapy. Curr Pharm Des 10:1341-53

Gharat, L; Taneja, R; Weerapreeyakul, N et al. (2001) Targeted drug delivery systems 6: Intracellular bioreductive activation, uptake and transport of an anticancer drug delivery system across intestinal Caco-2 cell monolayers. Int J Pharm 219:1-10

Killian, D M; Chikhale, P J (2001) A bioreversible prodrug approach designed to shift mechanism of brain uptake for amino-acid-containing anticancer agents. J Neurochem 76:966-74

Weerapreeyakul, N; Hollenbeck, R G; Chikhale, P J (2000) Stability of bioreductive drug delivery systems containing melphalan is influenced by conformational constraint and electronic properties of substituents. Bioorg Med Chem Lett 10:2391-5